Status:

COMPLETED

Compliance Survey of ADHD Medication for Optimal Satisfaction (COSMOS)

Lead Sponsor:

Johnson & Johnson Taiwan Ltd

Conditions:

Attention Deficit Disorder With Hyperactivity

Eligibility:

All Genders

6-16 years

Brief Summary

The survey is designed to identify non-compliant Attention Deficit Hyperactivity Disorder (ADHD) patients who are currently on Immediate- Released Methylphenidate (IR-MPH) and observe any change in co...

Detailed Description

This is an Observational, survey study. The survey is designed to be administered in two stages. In the first stage, patients who were prescribed Immediate-Released Methylphenidate (IR-MPH) for over 3...

Eligibility Criteria

Inclusion

  • Patients with a clinical diagnosis of DSM-IV ADHD
  • Patients were previously treated with Immediate-Released Methylphenidate (IR-MPH) taken once a day, twice a day, three times a day, or four times a day over three months and who were also on IR-MPH the last month without severe adverse events or possible contraindications with MPH
  • Patients whose parent or guardian has signed and dated an informed consent to participate in the survey of drug compliance
  • Patients who are still at school

Exclusion

  • ADHD patients who have systematic disease or clinically significant gastrointestinal problems, including narrowing (pathologic or iatrogenic) of the gastrointestinal tract
  • ADHD patients also diagnosed with psychosis except for Conduct Disorder and Oppositional Defiant Disorder

Key Trial Info

Start Date :

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

February 1 2006

Estimated Enrollment :

591 Patients enrolled

Trial Details

Trial ID

NCT00460720

End Date

February 1 2006

Last Update

April 28 2010

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.